Modulation by bradykinin of angiotensin type 1 receptor-evoked RhoA activation of connective tissue growth factor expression in human lung fibroblasts
Authors:
- Linda TaylorLTLinda Taylor
- Bin LiuBLBin Liu
- Jun YuJYJun Yu
- Peter PolgarPPPeter Polgar
- 1 June 2006
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 290 (6) , L1291-L1299
Abstract
The mechanisms regulating the opposing physiological actions of bradykinin (BK) and angiotensin II (AngII) are not well understood. Here we investigate signaling interactions between these two effectors. Connective tissue growth factor (CTGF) expression in IMR-90, human lung fibroblasts, is used as the endpoint target. In these cells the BK B2 receptor (BKB2R) is expressed constitutively, while no binding of AngII is detected. An inducible expression system is used to insert AngII receptor 1 (AT1R) and to obtain a signal level in response to AngII at the magnitude of BK. AngII and BK activate G protein-coupled targets, arachidonate release from cellular phospholipid stores, and intracellular phosphatidylinositol turnover equally. Both activate ERK, JNK, and p38 equally. However, AngII activates, whereas BK inactivates, RhoA. AngII induces a rapid (1 h) CTGF mRNA expression. RhoA siRNA and RhoA activation inhibitor, Y-27632, markedly reduce the AngII effect. Simultaneous treatment with BK and AngII attenuates the AT1R action. Additionally, BK in the absence of AngII lowers CTGF mRNA expression below basal levels over a span of 4 h. An AT1R/BKB2R chimera lacking heterotrimeric G protein coupling continues to activate MAP kinases to the same extent as wild-type (WT) AT1R and BKB2R. However, the increase of CTGF mRNA expression by this mutant is low, almost identical with that obtained by the simultaneous treatment of the WT AT1R-expressing cells with BK and AngII. In this context the chimeric receptor displays the characteristics of both receptors. These data demonstrate that, in human lung fibroblasts, BK modulates the action of AngII through the small G protein RhoA, but in a Gαi/Gαq-independent manner.Keywords
This publication has 39 references indexed in Scilit:
- Polyamines inhibit apoptosis in porcine parthenotes developing in vitroMolecular Reproduction and Development, 2005
- Angiotensin II Induces Connective Tissue Growth Factor Gene Expression via Calcineurin-Dependent PathwaysThe American Journal of Pathology, 2003
- Acute and chronic NOS inhibition enhances α2- adrenoreceptor-stimulated RhoA and Rho kinase in rat aortaAmerican Journal of Physiology-Heart and Circulatory Physiology, 2002
- Intracellular third loops in AT1 and AT2 receptors determine subtype specificityLife Sciences, 2001
- Connective tissue growth factor in human liver cirrhosisLiver International, 2000
- v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformationProceedings of the National Academy of Sciences, 2000
- Enhanced Insulin-Like Growth Factor Binding Protein–Related Protein 2 (Connective Tissue Growth Factor) Expression in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary SarcoidosisAmerican Journal of Respiratory Cell and Molecular Biology, 1999
- Angiotensin II Activates RhoA in Cardiac MyocytesCirculation Research, 1998
- Human foetal lung (IMR-90) cells: Myofibroblasts with smooth muscle-like contractile propertiesCell Motility, 1996
- Angiotensin II Receptor Pharmacology1994